Welcome to our dedicated page for Mereo Biopharma SEC filings (Ticker: MREO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mereo BioPharma Group plc (NASDAQ: MREO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed with the Securities and Exchange Commission. These filings offer primary-source information on Mereo’s financial condition, clinical development updates, and material corporate events.
Mereo’s Form 8-K filings, for example, have furnished press releases covering quarterly financial results, cash and cash equivalents, and recent corporate highlights. They also describe key clinical milestones, such as the progress of the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta, Data Monitoring Committee recommendations to proceed to final analysis, and subsequent top-line results. Other 8-K reports outline developments in the company’s pipeline, including partnering activities and regulatory designations for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease.
Through this page, users can follow how Mereo reports its operating performance, research and development spending, and capital structure over time via its SEC submissions. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the implications of new 8-Ks, 10-Ks or 10-Qs without reading every line.
Investors interested in MREO can use the filings page to monitor material updates on clinical programs, financing, and corporate agreements as they are reported to the SEC. Real-time access, combined with AI-generated explanations, supports efficient review of Mereo BioPharma’s regulatory history and ongoing disclosure record.
Mereo BioPharma Group plc director Jeremy Bender reported equity awards rather than open-market trades. On February 26, 2026, he received share options for 66,000 shares at a price of $0.00 per share, vesting in substantially equal monthly installments over one year from the grant date.
He also acquired 117,533 deferred restricted stock units, granted in lieu of annual cash compensation, which vest in substantially equal monthly installments over the plan year following the grant date. Each American Depositary Share represents five ordinary shares, and payment of these deferred units in ADSs will generally occur 180 days after separation of service.
PAKIANATHAN DEEPIKA reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Deepika Pakianathan was granted share options covering 66,000 shares on February 26, 2026. The options have a right to buy the company’s shares at a price of $0.0000 per share.
The grant vests in substantially equal monthly installments over one year from the February 26, 2026 grant date, meaning portions of the award become exercisable each month during that period.
Jenkins Annalisa reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group director Annalisa Jenkins received new equity-based compensation awards. She was granted 66,000 share options with a right to buy shares at no initial cost and 106,848 deferred restricted stock units, both dated February 26, 2026.
The share options vest in substantially equal monthly installments over one year from the grant date. The deferred restricted stock units were elected in lieu of annual cash compensation, vest monthly over the following plan year, and are generally settled in American Depositary Shares about 180 days after service ends.
WYZGA MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Michael S. Wyzga reported receiving a grant of 66,000 share options on February 26, 2026. These options are a right to buy shares and were awarded for no cash payment at grant. The award vests in substantially equal monthly installments over one year from the February 26, 2026 grant date. Each American Depositary Share represents five ordinary shares of the company.
Mereo BioPharma Group plc received an amended Schedule 13G/A from investment entities affiliated with Northpond, including Northpond Ventures funds and Michael P. Rubin, stating they beneficially own 0 ordinary shares, representing 0.0% of the class, as of December 31, 2025.
The filing clarifies that CUSIP 589492107 applies to the American Depositary Shares, with each ADS representing five ordinary shares. The reporting persons also certify that the securities referenced were not acquired or held for the purpose of changing or influencing control of Mereo BioPharma.
Mereo BioPharma Group plc has received a Nasdaq notice that its American Depositary Shares have not met the required minimum bid price of $1.00 for 30 consecutive business days, putting its Nasdaq Capital Market listing at risk.
The company has 180 calendar days, until August 17, 2026, to regain compliance by having a closing bid price of at least $1.00 for 10 consecutive business days, a period Nasdaq staff may extend at its discretion. If compliance is not restored by then, Mereo could receive a further 180-day grace period if it meets other Nasdaq initial listing standards and commits to curing the deficiency. Failing that, the ADSs may be delisted, though the company could appeal. The ADSs continue to trade under “MREO,” and management states business operations are not currently affected, while acknowledging there is no assurance it will regain or maintain Nasdaq listing compliance.
Mereo Biopharma Group plc received an amended Schedule 13G/A from Janus Henderson Group plc, reporting that, as of 12/31/2025, it beneficially owned 0 ordinary shares of Mereo and represented 0.0% of the class. Janus Henderson is the ultimate parent of several investment advisers whose client accounts (the Managed Portfolios) may hold Mereo shares, but these portfolios have the right to all dividends and sale proceeds. Janus Henderson and its asset managers report no voting or dispositive power over Mereo shares and disclaim ownership of related economic rights. The filing also notes that none of the Managed Portfolios owns more than five percent of Mereo’s ordinary shares and that any securities were acquired and held in the ordinary course of business, not to change or influence control of the company.
Mereo BioPharma Group plc received an amended Schedule 13G/A (Amendment No. 2) from several Frazier Life Sciences investment entities and their related managing members. The filing states that each reporting person beneficially owns 0 ordinary shares, or 0.0% of the class, of Mereo’s ordinary shares represented by American Depositary Shares as of 12/31/2025. The group also certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the company.
Mereo BioPharma Group plc granted new share options to Chief Scientific Officer John A. Lewicki on February 1, 2026. The awards cover 139,913 share options with a $0.44 exercise price, 46,637 share options with a $1.00 exercise price, and 145,000 share options with a $0.44 exercise price, all over American Depositary Shares.
For the 139,913 options, 25% of the underlying shares vest on February 1, 2027, with the rest vesting in equal monthly installments over the following three years. The 145,000 options vest in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma Group plc.
Mereo BioPharma Group plc reported that officer Alexandra Hughes-Wilson received new share option grants on February 1, 2026. The awards cover 183,750 American Depositary Shares (ADS) at an exercise price of $0.44, 61,250 ADS at $1.00, and 195,000 ADS at $0.44.
For the 183,750-ADS option, 25% vests on February 1, 2027, with the rest vesting in equal monthly installments over the next three years. The 195,000-ADS option vests in substantially equal monthly installments over one year from the February 1, 2026 grant date. Each ADS represents five ordinary shares of Mereo BioPharma.